Bio-Gene Technology Limited (ASX:BGT)
0.0150
-0.0005 (-3.23%)
Nov 20, 2026, 3:24 PM AEDT
Bio-Gene Technology Market Cap
Bio-Gene Technology has a market cap or net worth of 6.57 million as of November 19, 2026. It is the 44,890th most valuable company in the world and the 1,399th biggest in Australia. Its market cap has decreased by 25.73% in one year.
Market Cap
6.57M
Enterprise Value
4.63M
Revenue
n/a
Global Rank
Country Rank
#1,399 Australia
PE Ratio
n/a
ChartMarket Cap Chart
Since November 29, 2017, Bio-Gene Technology's market cap has decreased from 20.89M to 6.57M, a decrease of -68.55%. That is a compound annual growth rate of -12.08%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 20, 2026 | 6.57M | -6.35% |
| Dec 29, 2025 | 7.02M | -18.97% |
| Dec 30, 2024 | 8.66M | -28.33% |
| Dec 29, 2023 | 12.08M | -32.09% |
| Dec 29, 2022 | 17.79M | -48.81% |
| Dec 31, 2021 | 34.76M | 61.59% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Nov 29, 2017 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Patrys | 13.39M |
| Radiopharm Theranostics | 13.01M |
| Noxopharm | 12.03M |
| Immuron | 11.95M |
| Cambium Bio | 10.30M |
| AdAlta | 9.64M |
| Tissue Repair | 6.65M |
| Invex Therapeutics | 6.39M |